# InnovAge Holding Corp.: Form 10-Q for the period ended Dec 31, 2024

- Company: [InnovAge Holding Corp.](/companies/innv.md) (CIK 1834376)
- Form: 10-Q
- Filed: 2025-02-04
- Accepted by EDGAR: Feb 4, 2025, 17:03 ET
- Period: 2024-12-31
- Accession: 0001834376-25-000003
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1834376/000183437625000003/innv-20241231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1834376/000183437625000003/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-10-01 to 2024-12-31 | $209.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2024-07-01 to 2024-12-31 | $414.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2024-10-01 to 2024-12-31 | $37.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2024-07-01 to 2024-12-31 | $71.6m | us-gaap:GrossProfit |
| Operating income | 3 months, 2024-10-01 to 2024-12-31 | −$12.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-07-01 to 2024-12-31 | −$17.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-10-01 to 2024-12-31 | $34.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-07-01 to 2024-12-31 | $437.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-10-01 to 2024-12-31 | −$13.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-07-01 to 2024-12-31 | −$18.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-10-01 to 2024-12-31 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2024-07-01 to 2024-12-31 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-10-01 to 2024-12-31 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2024-07-01 to 2024-12-31 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-10-01 to 2024-12-31 | 135,439,668 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-07-01 to 2024-12-31 | 135,604,751 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-07-01 to 2024-12-31 | −$763.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-07-01 to 2024-12-31 | $3.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-12-31 | $46.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | $168.0m | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | $524.8m | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | $145.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-12-31 | $246.8m | us-gaap:Liabilities |
| Long-term debt | at 2024-12-31 | $59.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-12-31 | $3.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-12-31 | $248.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 65,185 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to our management. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly due to numerous known and unknown risks and uncertainties, including those discussed below and in the section entitled “Cautionary Note on Forward-Looking Statements.” Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (“2024 10-K”).*

### Overview

InnovAge Holding Corp. (“InnovAge”) became a public company in March 2021. As of December 31, 2024, the Company served approximately 7,480 PACE participants, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia.

### Trends and Uncertainties Affecting the Company

*Increased cost of care.* In the second quarter of fiscal year 2025, operating expenses increased $30.9 million, or 16.2%, compared to the second quarter of fiscal year 2024 due to census growth and increased cost of care per participant primarily as a result of increased salaries, wages and benefits associated with increased headcount and higher wage rates. Additionally, total external provider costs increased in the six month period ended December 31, 2024 compared to 2023 due to census growth partially offset by a reduction in cost per participant as a result of efforts to mitigate the effects of rising costs. In fiscal year 2024 and through the first two quarters of fiscal year 2025, we continued to strengthen our payer capabilities and reduced external provider costs per participant, which we believe to be a result of our maturing clinical value initiatives, which we began implementing in fiscal year 2023, and our operational value initiatives, which we began implementing in fiscal year 2024. While we expect to continue to experience elevated operating expenses through fiscal year 2025 for the reasons stated above, we also expect that our clinical value initiatives and operational value initiatives will help offset increasing cost of care.

*Census and capitation revenue.* We experienced, and continue to experience, delays and increased gaps in eligibility both for new enrollments and Medicaid redetermination applications during fiscal years 2024 and 2025 as a result of processing delays and other enrollment and redetermination procedures that vary by State and county. Specifically, in the State of California, processing delays have resulted in our inability to collect a portion of accounts receivables from the State leading to higher allowances against accounts receivable and corresponding write-offs. We are working to increase the proportion of new enrollments submitted prior to the first enrollment deadline each month to minimize enrollment efforts required by the State. We expect to continue mitigating measures during the remainder of fiscal year 2025, which include utilizing State approved third-party eligibility partners to expedite applications and escalating delayed cases to State administrators. During fiscal year 2024 and the first two quarters of fiscal year 2025, these delays and eligibility gaps have not had a material effect on the Company's financial statements or operations. We will continue to assess the situation as it evolves.

*Labor market*. The healthcare sector continues to experience a complex set of challenges in hiring additional professionals. Specifically, the demand for healthcare services has been steadily increasing due to an aging population and a greater focus on health and wellness in society. In addition, there are systemic challenges related to workforce training and the pipeline of qualified professionals, which have not kept pace with this growing demand. Wage pressure in the healthcare industry is a significant concern. Wage pressure arises when there is a high demand for healthcare services but a limited supply of qualified professionals, leading to increased competition for workers and upward pressure on wages. The rapidly aging population has increased the demand for healthcare services, especially for geriatrics. Simultaneously, many experienced healthcare workers are reaching retirement age, reducing the workforce supply.

In addition, an aging population combined with a shortage of clinicians, creates pressures and increased demand on the limited number of residential facilities. There is uncertainty regarding the access of our participants to residential facilities.

The high demand for such facilities may lead such facilities prioritizing patients who are private payors to avoid the frequently changing Medicare and Medicaid program reimbursement rates and rules, annual caps and regulatory requirements.

Additionally, as a result of the adoption of California Senate Bill No. 525 ("SB 525"), which raises minimum wage for many California healthcare workers and will impact many of our contractors and other third-party providers, combined with other macroeconomic factors, our California centers have received provider requests to increase rates to cover their increased labor costs. As a result of competition generated by SB 525 and other California market conditions, we have received rate increases from third party vendors, including home health and care partner services, increasing our cost of care in California. We also increased our wages for impacted healthcare workers and other comparable market positions in the California market. These increases did not have a material impact on our cost of care or labor costs, financial statements or operations for fiscal year 2024 or the three and six months ended December 31, 2024. We will continue to evaluate the impact of this and other similar future legislation on our business. For additional information on the various risks posed by macroeconomic events, regulation, and employee matters, please see the section entitled “Risk Factors” included in Part I, Item 1A of our 2024 10-K.

### Key Factors Affecting Our Performance

Our historical financial performance has been, and we expect our financial performance in the future to be, driven by the following factors:

- *Our participants.* We focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors. We directly contract with government payors, such as Medicare and Medicaid, through PACE and receive a capitated risk-adjusted payment to manage the totality of a participant’s medical care across all settings. InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (“MA”) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we believe we manage a higher acuity population, with an average risk adjustment factor (“RAF”) score of 2.45 based on InnovAge data as of December 31, 2024; and (ii) we have Medicaid spend in addition to Medicare. Our participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive per member, per month (“PMPM”) payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based on the underlying medical conditions and frailty of each participant. We continue to strengthen our expanding payer capabilities so that our revenue more accurately reflects the acuity of the populations we serve.
- *Our ability to grow enrollment and capacity within existing centers.* We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including sanctions issued by regulators or suspensions of State attestations required to open new de novo centers.
- *Our ability to maintain high participant satisfaction and retention.* Our comprehensive individualized care model and frequency of interaction with participants generates high levels of participant satisfaction. Our average participant tenure was 3.1 years as of December 31, 2024, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 6.9% annually over the last three fiscal years.
- *Effectively managing the cost of care for our participants*. We receive capitated payments to manage the totality of a participant’s medical care across all settings. The risk pool of our population is highly acute. Together with the factors disclosed above (increased salaries, wages and benefits,annual increases in assisted living and nursing facility unit cost and general medical inflation) our external provider costs and cost of care, excluding depreciation and amortization, represented approximately 83% of our revenue in the six months ended December 31, 2024.
- *Center-level Contribution Margin*. The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. As we serve more participants in existing

centers, we expect to leverage our fixed cost base at those centers and increase the value of a center to our business increases over time.

- *Our ability to expand via de novo centers within existing and new markets.* Several factors can affect our ability to open de novo centers, including sanctions issued by regulators, legal, community or other obstacles in the construction of such centers, and our ability to hire and train enough workers to ramp up these centers to maturity. In response to an audit to our Sacramento center and a medical review of our San Bernardino center, which have been previously disclosed, the California Department of Health Care Services (“DHCS") notified us that it was suspending its attestations in support of the planned de novo center in Downey and the recently acquired planned de novo center in Bakersfield. CMS has closed its process and DHCS's process is ongoing. While the planned California de novo centers are precluded from opening at this time, DHCS notified us that it would consider restoring the State Attestations upon our successful remediation of the deficiencies raised in our Sacramento center and its completion of the medical review (and any potential resultant remediation that may be required) in our San Bernardino center.
- *Execute tuck-in acquisitions and partnerships.* Since fiscal year 2019, we have acquired and integrated four PACE organizations for a total of eight operational centers (excluding the PACE center in Bakersfield, California, which is not yet operational). These acquisitions represent expansion of our InnovAge Platform into one new state and five new markets. By bringing acquired organizations under the InnovAge Platform, we hope to further realize revenue growth and improve operational efficiency and care delivery post-integration. We also have pursued and intend to continue pursuing additional relationships with key stakeholders, existing organizations and other care providers in order to form partnerships in target geography, such as the joint venture we entered into at our Orlando PACE center with Orlando Health during the fourth quarter of fiscal year 2024. On January 2, 2025, with the goal of supporting our growth and improving pharmacy cost-management, we completed the acquisition of certain pharmacy assets from Tabula Rasa HealthCare Group, Inc. (“TRHC”), a leading pharmacy care management company, for a total purchase price of $4.8 million. TRHC will provide management services to the pharmacy business pursuant to a Management Services Agreement with an initial term of five years.
- *Our ability to maintain high quality of regulatory compliance*. The Company's priority is to continue to maintain high quality of regulatory compliance in all its centers.
- *Contracting with government payors*. Our economic model relies on our capitated arrangements with government payors, namely Medicare and Medicaid. We view the government not only as a payor but also as a key partner in our efforts to expand into new geographies and access more participants in our existing markets. Maintaining, supporting and growing these relationships in existing markets as well as new geographies, is critical to our long-term success.
- *Investing to support growth*. We intend to continue investing in our centers, value-based care model, and sales and marketing organization to support long-term growth. We expect our expenses to increase in absolute dollars for the foreseeable future to support our growth due, partially, to additional costs we incur in connection with our audits to our centers, remediation plans and current and potential legal and regulatory proceedings. We plan to invest in future growth judiciously and maintain focus on managing our results of operations. We are investing to increase our sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends. Accordingly, in the short term, we expect the activities noted above to increase our expenses as a percentage of revenue, but in the longer term, we anticipate that these investments will positively impact our business and results of operations.
- *Seasonality of our business*. Our operational and financial results, including medical costs and per-participant revenue true-ups, will experience some variability depending upon the time of year in which they are measured. Medical costs vary most significantly as a result of (i) the weather, with certain illnesses, such as the influenza and COVID-19 viruses, being more prevalent during colder months of the year, which generally increases per-participant costs, and (ii) the number of business days in a period, with shorter periods generally having lower medical costs, all else equal. Per-participant revenue true-ups represent the difference between our estimate of per-participant capitation revenue to be received and actual revenue received from CMS, which is based on CMS’s determination of a participant’s RAF score as measured twice per year and is based on the evolving acuity of a participant. Where there is a difference between our estimate and the final determination from CMS, we may record either an increase or decrease in true-up revenue. Historically, these

true-up payments typically occur between May and August, but the timing of these payments is determined by CMS, and we have neither visibility into nor control over the timing of such payments. The variability of participant enrollments during the open enrollment period has also been impacted by additional offerings by MA and other competitors. We believe that, as a result of these additional offerings, we experienced higher than expected disenrollments during the third quarter of fiscal 2024.

### Components of Results of Operations

### Revenue

*Capitation Revenue*. In order to provide comprehensive services to manage the totality of a participant’s medical care across all settings, we receive fixed or capitated fees per participant that are paid monthly by Medicare, Medicaid, Veterans Affairs (“VA”) and private pay sources.

Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. The PACE state contracts between us and the respective state Medicaid administering agency are renewed annually each June 30 in all states other than California and Pennsylvania, which contract on a calendar-year basis. We are currently operating in good standing under each of our PACE state contracts. For a discussion of our revenue recognition policies, please see *Critical Accounting Estimates* below and Note 2 “Summary of Significant Accounting Policies” to our consolidated financial statements included in our 2024 10-K.

*Other Service Revenue.* Other service revenue primarily consists of revenues derived from state food grants and rent revenues. For a discussion of our revenue recognition policies, please see *Critical Accounting Estimates* below and Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our 2024 10-K.

### Operating Expenses

*External Provider Costs.* External provider costs consist primarily of the costs for medical care provided by non-InnovAge providers. We separate external provider costs into four categories: inpatient (e.g., hospital), housing (e.g., assisted living and skilled nursing facility), outpatient and pharmacy. In aggregate, external provider costs represent the largest portion of our expenses.

*Cost of Care, Excluding Depreciation and Amortization.* Cost of care, excluding depreciation and amortization, includes the costs we incur to operate our care delivery model. This includes costs related to salaries, wages and benefits for IDT and other center-level staff, participant transportation, medical supplies, occupancy, insurance and other operating costs. IDT employees include medical doctors, registered nurses, social workers, physical, occupational, and speech therapists, nursing assistants, and transportation workers. Other center-level employees include clinic managers, dieticians, activity assistants and certified nursing assistants. Cost of care excludes any expenses associated with sales and marketing activities incurred at a local level as well as any allocation of our corporate, general and administrative expenses. A portion of our cost of care, including our employee-related costs, is directly related to the number of participants cared for in a center. The remainder of our cost of care is fixed relative to the number of participants we serve, such as occupancy and insurance expenses. As a result, as revenue increases due to census growth, cost of care, excluding depreciation and amortization, moderately decreases as a percentage of revenue. As we open new centers, we expect cost of care, excluding depreciation and amortization, to increase in absolute dollars due to higher census and facility related costs.

*Sales and Marketing.* Sales and marketing expenses consist of employee-related expenses, including salaries, commissions, and employee benefits costs, for all employees engaged in marketing, sales, community outreach and sales support as well as financial eligibility support for both prospective and existing participants. These employee-related expenses capture all costs for both our field-based and corporate sales and marketing teams. Sales and marketing expenses also include local and centralized advertising costs, as well as the infrastructure required to support our marketing efforts. We expect these costs to increase in absolute dollars over time as we continue to grow our participant census. We evaluate our sales and marketing expenses relative to our participant growth and will invest more heavily in sales and marketing from time-to-time to the extent we believe such investment can accelerate our growth without negatively affecting profitability.

*Corporate, General and Administrative Expenses.* Corporate, general and administrative expenses include employee-related expenses, including salaries and related costs. In addition, general and administrative expenses include all corporate technology and occupancy costs associated with our corporate office. We expect our general and administrative expenses to increase in absolute dollars due to the additional legal, accounting, insurance, investor relations and other costs that we incur as a public company, as well as other costs associated with compliance and continuing to grow our business. However, we anticipate general and administrative expenses to decrease as a percentage of revenue over the long term, although such expenses may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses.

*Depreciation and Amortization.* Depreciation and amortization expenses are primarily attributable to our buildings and leasehold improvements and our equipment and vehicles. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful life or lease terms, to the extent the assets are being leased.

For more information relating to the components of our results of operations, see *Results of Operations* below and Note 2 “Summary of Significant Accounting Policies” to our consolidated financial statements included in our 2024 10-K.

### Results of Operations

The following table sets forth our consolidated results of operations for the periods presented:

*in thousands*

| Revenues | Three Months Ended December 31, 2024 | 2023 | Six Months Ended December 31, 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| Capitation revenue | $208,674 | $188,561 | $413,474 | $370,734 |
| Other service revenue | 325 | 337 | 667 | 648 |
| Total revenues | 208,999 | 188,898 | 414,141 | 371,382 |
| **Expenses** |  |  |  |  |
| External provider costs | 107,873 | 100,964 | 215,087 | 200,322 |
| Cost of care, excluding depreciation and amortization | 64,061 | 54,321 | 127,447 | 109,570 |
| Sales and marketing | 7,704 | 5,859 | 14,196 | 11,237 |
| Corporate, general and administrative | 28,103 | 25,249 | 55,638 | 54,197 |
| Depreciation and amortization | 5,319 | 4,290 | 10,730 | 8,559 |
| Impairment of right-of-use asset and construction in progress | 8,495 | — | 8,495 | — |
| Total expenses | 221,555 | 190,683 | 431,593 | 383,885 |
| **Operating Loss** | (12,556) | (1,785) | (17,452) | (12,503) |
| **Other Income (Expense)** |  |  |  |  |
| Interest expense, net | (760) | (935) | (1,408) | (1,596) |
| Other income (expense) | (157) | 874 | 80 | 1,517 |
| Gain (loss) on equity method investment | 16 | (1,882) | 16 | (1,882) |
| Total other expense | (901) | (1,943) | (1,312) | (1,961) |
| **Loss Before Income Taxes** | (13,457) | (3,728) | (18,764) | (14,464) |
| **Provision for Income Taxes** | 34 | 93 | 437 | 319 |
| **Net Loss** | (13,491) | (3,821) | (19,201) | (14,783) |
| Less: net loss attributable to noncontrolling interests | (270) | (374) | (1,051) | (1,032) |
| **Net Loss Attributable to InnovAge Holding Corp.** | $(13,221) | $(3,447) | $(18,150) | $(13,751) |

34

### Revenues

*in thousands*

|  | Three Months Ended December 31, 2024 | 2023 | Change $% |  | Six Months Ended December 31, 2024 | 2023 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Capitation revenue | $208,674 | $188,561 | $20,113 | 10.7% | $413,474 | $370,734 | $42,740 | 11.5% |
| Other service revenue | 325 | 337 | (12) | (3.6)% | 667 | 648 | 19 | 2.9% |
| Total revenues | $208,999 | $188,898 | $20,101 | 10.6% | $414,141 | $371,382 | $42,759 | 11.5% |

*Capitation revenue.* Capitation revenue was $208.7 million for the three months ended December 31, 2024, an increase of $20.1 million, or 10.7%, compared to $188.6 million for the three months ended December 31, 2023. This increase was driven by a $0.7 million, or 0.3%, increase in capitation rates coupled with $19.4 million, or 10.3%, increase in member months for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023. The increase in capitation rates for the three months ended December 31, 2024 was primarily driven by (i) a 5.2% annual increase in Medicaid capitation rates as determined by the States partially offset by revenue reserve and (ii) a 1.6% decrease in Medicare capitation rates as a result of an out of cycle risk score true up payment received in the prior year. The increase in member months was primarily due to growth in our California and Colorado centers and to a lesser extent due to the addition of de novo centers in Florida and the Concerto acquisition.

Capitation revenue was $413.5 million for the six months ended December 31, 2024, an increase of $42.7 million, or 11.5%, compared to $370.7 million for the six months ended December 31, 2023. This increase was driven by a $6.2 million, or 1.5%, increase in capitation rates coupled with a $36.6 million, or 9.9%, increase in member months for the six months ended December 31, 2024 as compared to the six months ended December 31, 2023. The increase in capitation rates includes a 5.5% increase in Medicaid rates partially offset by revenue reserve and a 0.4% decrease in Medicare rates due to an out of cycle risk score true up payment received in the prior year.

### Operating Expenses

*in thousands*

|  | Three Months Ended December 31, 2024 | 2023 | Change $% |  | Six Months Ended December 31, 2024 | 2023 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| External provider costs | $107,873 | $100,964 | $6,909 | 6.8% | $215,087 | $200,322 | $14,765 | 7.4% |
| Cost of care (excluding depreciation and amortization) | 64,061 | 54,321 | 9,740 | 17.9% | 127,447 | 109,570 | 17,877 | 16.3% |
| Sales and marketing | 7,704 | 5,859 | 1,845 | 31.5% | 14,196 | 11,237 | 2,959 | 26.3% |
| Corporate, general, and administrative | 28,103 | 25,249 | 2,854 | 11.3% | 55,638 | 54,197 | 1,441 | 2.7% |
| Depreciation and amortization | 5,319 | 4,290 | 1,029 | 24.0% | 10,730 | 8,559 | 2,171 | 25.4% |
| Impairment of right-of-use asset and construction in progress | $8,495 | $— | 8,495 | 100.0% | $8,495 | $— | 8,495 | 100.0% |
| Total operating expenses | $221,555 | $190,683 | $30,872 |  | $431,593 | $383,885 | $47,708 |  |

*External provider costs.* External provider costs were $107.9 million for the three months ended December 31, 2024, an increase of $6.9 million, or 6.8%, compared to $101.0 million for the three months ended December 31, 2023. The increase was driven by an increase of $10.4 million, or 10.3%, in member months partially offset by a decrease of $3.5 million, or 3.1% in cost per participant for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023. The decrease in cost per participant for the three months ended December 31, 2024 was primarily driven by a decrease in inpatient, assisted living, permanent nursing facility, and short stay skilled nursing facility utilization coupled with a decrease in external hospice care associated with the transition of this function to internal clinical resources. This was partially offset by an increase in inpatient unit cost, an annual increase in pharmacy cost, and an annual increase in assisted living and permanent nursing facility unit cost.

External provider costs were $215.1 million for the six months ended December 31, 2024, an increase of $14.8 million, or 7.4%, compared to $200.3 million for the six months ended December 31, 2023. This increase was driven by an increase of $19.8 million, or 9.9%, in member months partially offset by a decrease of $5.0 million, or 2.3%, in cost per participant for the six months ended December 31, 2024 as compared to the six months ended December 31, 2023. The decrease in cost per participant was primarily driven by a decrease in inpatient, assisted living, permanent nursing facility and short stay skilled nursing facility utilization coupled with a decrease in external hospice care associated with the transition of this function to internal clinical resources. This was partially offset by an increase in inpatient unit cost, an annual increase in pharmacy cost, and an annual increase in assisted living and permanent nursing facility unit cost.

*Cost of care (excluding depreciation and amortization).* Cost of care (excluding depreciation and amortization) expense was $64.1 million for the three months ended December 31, 2024, an increase of $9.7 million, or 17.9%, compared to $54.3 million for the three months ended December 31, 2023, due to an increase of $4.1 million, or 6.9%, in cost per participant coupled with an increase of $5.6 million, or 10.3%, in member months. The increase for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023 was primarily driven by (i) a $6.6 million increase in salaries, wages and benefits associated with increased headcount and higher wage rates, (ii) $0.9 million in contract provider expense in California associated with growth, (iii) $0.9 million in de novo occupancy and administrative expense associated with opening centers in Florida and the Concerto acquisition, and (iv) $0.8 million in increased software license fees.

Cost of care (excluding depreciation and amortization) expense was $127.4 million for the six months ended December 31, 2024, an increase of $17.9 million, or 16.3%, compared to $109.6 million for the six months ended December 31, 2023, due to an increase of $7.1 million, or 5.9%, in cost per participant coupled with an increase of $10.8 million, or 9.9%, in member months. The increase for the six months ended December 31, 2024 as compared to the six months ended December 31, 2023 was primarily driven by (i) a $12.3 million increase in salaries, wages, and benefits associated with increased headcount and higher wage rates, (ii) $1.6 million in increased software license fees, (iii) $1.6 million in de novo occupancy and administrative expense associated with opening centers in Florida and the Concerto acquisition, (iv) $1.5 million in contract provider expense in California associated with growth, and (v) $0.5 million in contract provider recruiting expense.

*Sales and marketing.* Sales and marketing expenses were $7.7 million for the three months ended December 31, 2024, an increase of $1.8 million, or 31.5%, compared to $5.9 million for the three months ended December 31, 2023, primarily due to increased headcount and marketing expense to support growth.

Sales and marketing expenses were $14.2 million for the six months ended December 31, 2024, an increase of $3.0 million, or 26.3%, compared to $11.2 million for the six months ended December 31, 2023 primarily due to increased headcount and marketing spend to support growth.

*Corporate, general and administrative.* Corporate, general and administrative expenses were $28.1 million for the three months ended December 31, 2024, an increase of $2.9 million, or 11.3%, compared to $25.2 million for the three months ended December 31, 2023. This increase for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023 was primarily due to (i) $1.9 million increase in employee compensation and benefits as the result of an increase in headcount and wage rates to support compliance and bolster organizational capabilities, (ii) $0.9 million in consulting expense primarily in support of the pharmacy acquisition, (iii) $0.7 million in fees associated with claims payment integrity audits, (iv) $0.4 million increase in software license fees, and (v) $0.5 million in recruiting fees. These increases in cost were partially offset by (i) $1.4 million reduction in consulting expense associated with improving organizational capabilities including the transition to a new electronic medical record ("EMR") system and (ii) $0.5 million reduction in insurance expense.

Corporate, general and administrative expenses were $55.6 million for the six months ended December 31, 2024, an increase of $1.4 million, or 2.7%, compared to $54.2 million for the six months ended December 31, 2023. This increase for the six months ended December 31, 2024 as compared to the six months ended December 31, 2023 was primarily due to (i) $4.3 million increase in employee compensation and benefits as the result of an increase in headcount and wage rates to support compliance and bolster organizational capabilities, (ii) $0.9 million in fees associated with claims payment integrity audits, (iii) $0.6 million in recruiting fees (iv) $0.5 million in consulting expense, and (v) $0.4 million increase in software license fees. These increases in cost were partially offset by (i) $4.0 million reduction in consulting expense associated with improving organizational capabilities including the transition to a new EMR system and (ii) $1.0 million reduction in insurance expense.

*Impairment of right-of-use ("ROU") asset and construction in progress.* Impairment of ROU asset and construction in progress were $8.5 million for each of the three and six months ended December 31, 2024. This increase was due to the Company recording a $1.4 million impairment of operating lease ROU assets and a $7.1 million impairment of construction in progress during each of the three and six months ended December 31, 2024, related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing. There were no impairments recorded during the three and six months ended December 31, 2023.

### Other Expense

*in thousands*

|  | Three Months Ended December 31, 2024 | 2023 | Change $% |  | Six Months Ended December 31, 2024 | 2023 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense, net | $(760) | $(935) | $175 | (18.7)% | $(1,408) | $(1,596) | $188 | (11.8)% |
| Other income (expense) | (157) | 874 | (1,031) | (118.0)% | 80 | 1,517 | (1,437) | (94.7)% |
| Gain (loss) on equity method investment | 16 | (1,882) | 1,898 | (100.9)% | 16 | (1,882) | 1,898 | (100.9)% |
| Total other expense | $(901) | $(1,943) | $1,042 |  | $(1,312) | $(1,961) | $649 |  |

*Interest expense, net.* Interest expense, net, consists primarily of interest payments on our outstanding borrowings, net of interest income earned on our cash and cash equivalents and restricted cash. Interest expense, net was $0.8 million for the three months ended December 31, 2024, a decrease of $0.2 million, or 18.7%, compared to $0.9 million for the three months ended December 31, 2023. The decrease for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023 was primarily due to interest expense of $1.6 million, which was partially offset by interest income of $0.9 million from money market funds for the three months ended December 31, 2024. Interest expense of $1.8 million was partially offset by interest income of $0.9 million during the three months ended December 31, 2023.

Interest expense, net was $1.4 million for the six months ended December 31, 2024, a decrease of $0.2 million, or 11.8%, compared to $1.6 million for the six months ended December 31, 2023. This decrease for the six months ended December 31, 2024 as compared to the six months ended December 31, 2023 was due to interest expense of $3.4 million, which was partially offset by interest income of $2.0 million from money market funds for the six months ended December 31, 2024. Interest expense of $3.6 million was partially offset by interest income of $2.0 million during the six months ended December 31, 2023.

*Other income (expense).* Other income (expense) consists primarily of the net proceeds received from the sale of or disposal of property and equipment and unrealized gains and losses related to short-term investments. Other income for the three months ended December 31, 2024 decreased $1.0 million, or 118.0%, compared to the three months ended December 31, 2023. The decrease was primarily due to unrealized gains of $0.1 million for the three months ended December 31, 2024 compared to unrealized gains of $0.2 million for the three months ended December 31, 2023.

Other income (expense) for the six months ended December 31, 2024 decreased $1.4 million, or 94.7%, compared to the six months ended December 31, 2023. This decrease was primarily due to dividends received of $1.2 million during the six months ended December 31, 2023 compared to none in the current period.

*Gain (loss) on equity method investment.* Gain (loss) in equity method investment was negligible for the three and six months ended December 31, 2024, an increase of $1.9 million, or 100.9%, compared to $1.9 million for the three and six months ended December 31, 2023. The increase was due to the recognized impairment losses of $1.9 million related to our minority equity investment in Jetdoc during the three and six months ended December 31, 2023.

### Provision for Income Taxes

The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Senior Housing Thornton, LLC ("SH1") and InnovAge Sacramento have elected to be taxed as partnerships, and no provision (benefit) for income taxes for SH1 or InnovAge Sacramento is included in the condensed consolidated financial statements. Further, the Company entered into a joint venture called InnovAge Florida PACE –

Orlando on May 28, 2024 and its members elected to be taxed as a partnership. No provision (benefit) for income taxes for InnovAge Orlando is included in the condensed consolidated financial statements for activity occurring from joint venture formation date through the balance of the fiscal year.

A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.

During the three months ended December 31, 2024 and 2023, we reported an income tax expense of $0.03 million and $0.1 million, respectively. During the six months ended December 31, 2024 and 2023, we reported an income tax expense of $0.4 million and $0.3 million, respectively. The decrease of $0.1 million for the six months ended December 31, 2024 compared to the six months ended December 31, 2023, was primarily due to (i) our pretax book loss recognized during the six months ended December 31, 2024, as compared to pretax book loss recognized during the six months ended December 31, 2023, (ii) a discrete item to account for the impact of the decreasing Pennsylvania tax rate on our state deferred tax liabilities, and (iii) the change in our valuation allowance.

### Net Loss Attributable to Noncontrolling Interests.

SH1 is a Variable Interest Entity (“VIE”). The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 because it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for the convertible term loan held by SH1. The SH1 interest is reflected within equity as noncontrolling interests. Our share of earnings is recorded in the consolidated statements of operations and the share of the other noncontrolling interest holders’ earnings are recorded as net loss attributable to noncontrolling interests.

### Key Business Metrics and Non-GAAP Measures

In addition to our GAAP financial information, we review a number of operating and financial metrics, including the following key metrics and non-GAAP measures, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We believe these metrics provide additional perspective and insights when analyzing our core operating performance from period to period and evaluating trends in historical operating results. These key business metrics and non-GAAP measures should not be considered superior to, or a substitute for, and should be read in conjunction with, the GAAP financial information presented herein. These measures may not be comparable to similarly-titled performance indicators used by other companies.

*dollars in thousands*

| Key Business Metrics: | Six months ended December 31, 2024 | 2023 |
| --- | ---: | ---: |
| Centers(a) | 20 | 18 |
| Census(a)(b) | 7,480 | 6,780 |
| Total Member Months(a)(b) | 43,580 | 39,670 |
| Center-level Contribution Margin(c) | $71,607 | $61,490 |
| Center-level Contribution Margin as a % of revenue(c) | 17.3% | 16.6% |
| GAAP Measures: |  |  |
| Net loss | $(19,201) | $(14,783) |
| Net loss margin | (4.6)% | (4.0)% |
| Non-GAAP Measures: |  |  |
| Adjusted EBITDA(c) | $12,346 | $8,280 |
| Adjusted EBITDA Margin(c) | 3.0% | 2.2% |

(a) The Company operated 20 PACE centers as of December 31, 2024. Includes InnovAge Sacramento and InnovAge Orlando, which the Company owns and controls through joint ventures and are consolidated in our financial statements.

(b) Amounts are approximate.

(c) Center-level Contribution Margin, Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the period indicated, see below.

### Centers

We define our centers as those centers open for business and attending to participants at the end of a particular period.

### Census

Our census is comprised of our capitated participants for whom we are financially responsible for their total healthcare costs.

### Total Member Months

We define Total Member Months as the total number of participants multiplied by the number of months within a year in which each participant was enrolled in our program. We believe this is a useful metric as it more precisely tracks the number of participants we serve throughout the year.

### Center-level Contribution Margin

The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs. For purposes of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expenses or corporate, general and administrative expenses across our centers. Center-level Contribution Margin was $71.6 million and $61.5 million for the six months ended December 31, 2024 and 2023, respectively. The increase in Center-level Contribution Margin for the six months ended December 31, 2024 compared to the six months ended December 31, 2023 was primarily due to a 11.5% increase in total revenue, offset by a 10.5% increase in external provider costs and cost of care, excluding depreciation and amortization, during the same period. For more information relating to Center-level Contribution Margin, see Note 14 “Segment Reporting” to our condensed consolidated financial statements. A reconciliation of Center-level Contribution Margin to loss before income taxes, the most directly comparable GAAP measure, for each of the periods is as follows:

*(In thousands)*

|  | Six Months Ended December 31, 2024 PACE | All other(a) | Totals | Six Months Ended December 31, 2023 PACE | All other(a) | Totals |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Capitation revenue | $413,474 | $— | $413,474 | $370,734 | $— | $370,734 |
| Other service revenue | 174 | 493 | 667 | 153 | 495 | 648 |
| Total revenues | 413,648 | 493 | 414,141 | 370,887 | 495 | 371,382 |
| External provider costs | 215,087 | — | 215,087 | 200,322 | — | 200,322 |
| Cost of care, excluding depreciation and amortization | 127,150 | 297 | 127,447 | 109,267 | 303 | 109,570 |
| **Center-Level Contribution Margin** | 71,411 | 196 | 71,607 | 61,298 | 192 | 61,490 |
| Overhead costs(b) | 69,834 | — | 69,834 | 65,425 | 9 | 65,434 |
| Depreciation and amortization | 10,499 | 231 | 10,730 | 8,334 | 225 | 8,559 |
| Impairment of right-of-use asset and construction in progress | 8,495 | — | 8,495 | — | — | — |
| Interest expense, net | (1,320) | (88) | (1,408) | (1,506) | (90) | (1,596) |
| Other income (expense) | 80 | — | 80 | 1,517 | — | 1,517 |
| Gain (loss) on equity method investment | 16 | — | 16 | (1,882) | — | (1,882) |
| **Loss Before Income Taxes** | $(18,641) | $(123) | $(18,764) | $(14,332) | $(132) | $(14,464) |
| **Loss Before Income Taxes as a % of revenue** |  |  | (4.5)% |  |  | (3.9)% |
| **Center- Level Contribution Margin as a % of revenue** |  |  | 17.3% |  |  | 16.6% |

(a) Center-level Contribution Margin from a segment below the quantitative thresholds is attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments.

(b) Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.

### Adjusted EBITDA and Adjusted EBITDA Margin

We define Adjusted EBITDA as net loss adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlements, M&A diligence, transaction and integration, business optimization, EMR implementation, impairment of ROU asset and construction in progress, and loss on minority equity interest. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue. For the six months ended December 31, 2024 and 2023, net loss was $19.2 million and $14.8 million, respectively, representing a year-over-year decrease of 29.9%. Adjusted EBITDA was $12.3 million and $8.3 million, for the six months ended December 31, 2024 and 2023, respectively, representing a year-over-year increase of 49.1%. For the six months ended December 31, 2024, net loss margin was 4.6%, as compared to net loss margin of 4.0% for the six months ended December 31, 2023. For the six months ended December 31, 2024, our Adjusted EBITDA margin was 3.0%, as compared to our Adjusted EBITDA margin for the six months ended December 31, 2023 of 2.2%. The increase in Adjusted EBITDA and Adjusted EBITDA margin was primarily due to (i) increased capitation rates and (ii) lower per participant external provider costs, partially offset by (i) increased center-level headcount and wage rates associated with census growth and a competitive labor market and (ii) increased sales and marketing and corporate, general and administrative expense.

Adjusted EBITDA and Adjusted EBITDA margin are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net loss and net loss margin, respectively, as determined by GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin are appropriate measures of operating performance because the metrics eliminate the impact of revenue and expenses that do not relate to our ongoing business performance and certain noncash expenses, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that Adjusted EBITDA and Adjusted EBITDA margin help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net loss and net loss margin. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. The use of the term Adjusted EBITDA varies from others in our industry. Effective for the year ended June 30, 2024 and going forward, the Company revised its calculation of Adjusted EBITDA to no longer exclude de novo center development costs and to reflect the impact of other investment income. The presentation for the six months ended December 31, 2023 has been recast to conform to the current presentation.

A reconciliation of net loss to Adjusted EBITDA, the most directly comparable GAAP measure, for each of the periods is as follows:

|  | Three months ended December 31, 2024 | 2023 | Six months ended December 31, 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net loss | $(13,491) | $(3,821) | $(19,201) | $(14,783) |
| Interest expense, net | 760 | 935 | 1,408 | 1,596 |
| Other investment income(a) | 141 | (871) | (95) | (1,198) |
| Depreciation and amortization | 5,319 | 4,290 | 10,730 | 8,559 |
| Provision for income tax | 34 | 93 | 437 | 319 |
| Stock-based compensation | 1,873 | 1,766 | 4,035 | 3,589 |
| Litigation costs and settlement(b) | 1,405 | 198 | 4,464 | 1,905 |
| M&A diligence, transaction and integration(c) | 1,275 | 284 | 1,380 | 174 |
| Business optimization(d) | 58 | 774 | 693 | 2,933 |
| EMR implementation(e) | — | 1,370 | — | 3,304 |
| Impairment of right-of-use asset and construction in progress(f) | 8,495 | — | 8,495 | — |
| Loss on minority equity interest(g) | — | 1,882 | — | 1,882 |
| Adjusted EBITDA | $5,869 | $6,900 | $12,346 | $8,280 |

(a) Reflects investment income related to short-term investments included in our consolidated statement of operations. Effective for the year ended June 30, 2024 and going forward, the Company has revised the calculation for Adjusted EBITDA to reflect the impact of investment income. The presentation for the three and six months ended December 31, 2023 has been recast to reflect the impact of other investment income.

(b) Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. Refer to Note 9, "Commitments and Contingencies" to our condensed consolidated financial statements for more information regarding litigation by stockholders and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy.

(c) Reflects charges related to M&A transaction and integrations. The presentation for the three and six months ended December 31, 2023 has been recast to no longer exclude de novo center development costs.

(d) Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations.

For the three months ended December 31, 2024, this primarily includes costs related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the six months ended December 31, 2024, this includes (i) $0.4 million of costs associated with organizational restructure and (ii) $0.3 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the three months ended December 31, 2023, this includes (i) $0.4 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities and (ii) $0.4 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the six months ended December 31,2023, this includes (i) $2.2 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities, (ii) $0.3 million of costs associated with organizational restructure, and (iii) $0.4 million related to other non-recurring projects aimed at reducing costs and improving efficiencies.

(e) Reflects non-recurring expenses relating to the implementation of a new EMR vendor.

(f) Reflects impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing.

(g) Reflects impairment charges related to our minority equity interest in Jetdoc, Inc.

### Liquidity and Capital Resources

#### General

To date, we have financed our operations principally through cash flows from operations and through borrowings under our credit facilities, and from the sale of common stock in our IPO that occurred in March 2021. As of December 31, 2024, we had cash and cash equivalents of $46.1 million, a decrease of $10.8 million from June 30, 2024. The decrease in cash and cash equivalents was primarily due to timing of cash receipts for services provided and share repurchase activity. Our cash and cash equivalents primarily consist of highly liquid investments in demand deposit accounts and cash.

Our capital resources are generally used to fund (i) debt service requirements, the majority of which relate to the quarterly principal payments of the Term Loan Facility (as defined below) due 2026, (ii) finance and operating lease obligations, which are generally paid on a monthly basis and include maturities through 2028 and 2032, respectively, (iii) the operations of our business, (iv) income tax payments, which are generally due on a quarterly and annual basis, (v) capital additions, which include acquisitions and de novo centers, and (vi) share repurchases authorized under the Board approved program. We also plan to continue investing in resources and initiatives to provide necessary and quality services to our participants. Collectively, these obligations are expected to represent a significant liquidity requirement of our Company on both a short-term (next 12 months) and long-term (beyond 12 months) basis.

As of December 31, 2024, we had $64.1 million of long-term debt outstanding. As of December 31, 2024, we had future minimum operating lease payments under non-cancellable leases through the year 2037 of $38.8 million. We also had non-cancellable finance lease agreements with third parties through the year 2028 with future minimum payments of $19.5 million. For additional information, see Note 7, “Leases”, Note 8, “Long-Term Debt”, and Note 9, “Commitments and Contingencies” in our condensed consolidated financial statements.

We believe that our cash and cash equivalents and our cash flows from operations, available funds, and access to financing sources, including our Revolving Credit Facility (each discussed and defined below), will be sufficient to fund our operating and capital needs for the next 12 months and beyond. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our actual results could vary because of, and our future capital requirements will depend on, many factors, including our growth rate, our ability to retain and grow the number of PACE participants, and the expansion of sales and marketing activities and other costs of operating the business. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would be adversely affected.

On March 8, 2021, the Company entered into a credit agreement (as amended, the "2021 Credit Agreement") that consists of a senior secured term loan (the “Term Loan Facility”) of $75.0 million principal amount and a revolving credit facility (the “Revolving Credit Facility”) of $100.0 million maximum borrowing capacity. The borrowing capacity under the Revolving Credit Facility is subject (i) any issued amounts under our letters of credit and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. Principal on the Term Loan Facility is paid each calendar quarter in an amount equal to 1.25% of the initial term loan on closing date.

Outstanding principal amounts under the 2021 Credit Agreement accrue interest at a variable interest rate. As of December 31, 2024, the interest rate on the Term Loan Facility was 6.94%. Under the terms of the 2021 Credit Agreement, the Revolving Credit Facility fee accrues at 0.25% of the average daily unused amount and is paid quarterly. As of December 31, 2024, we had no borrowings outstanding, $5.2 million of letters of credit issued, and $94.8 million of remaining borrowing capacity under the Revolving Credit Facility. As of December 31, 2024, we also had $2.2 million principal amount outstanding under our convertible term loan. Monthly principal and interest payments for the convertible term loan are approximately $0.02 million, and the loan bears interest at an annual rate of 6.68%. The remaining principal balance is due upon maturity, which is August 20, 2030.

For more information about our debt, see Note 8 “Long-Term Debt” to our condensed consolidated financial statements.

Other than with respect to share repurchases, we currently intend to retain substantially all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and do not anticipate paying any cash dividends in the foreseeable future.

### Condensed Consolidated Statements of Cash Flows

Our condensed consolidated statements of cash flows for the six months ended December 31, 2024 and 2023 are summarized as follows:

*in thousands*

|  | Six months ended December 31, 2024 | 2023 | $ Change |
| --- | ---: | ---: | ---: |
| Net cash used in operating activities | $(763) | $(42,279) | $41,516 |
| Net cash provided by (used in) investing activities | 1,610 | (26,252) | 27,862 |
| Net cash used in financing activities | (11,716) | (4,638) | (7,078) |
| Net change in cash, cash equivalents and restricted cash | $(10,869) | $(73,169) | $62,300 |

*Operating Activities.* The change in net cash used in operating activities for the six months ended December 31, 2024 compared to the six months ended December 31, 2023 was primarily due to the net effect of (i) net loss of $19.2 million in the current year period compared to a net loss of $14.8 million in the prior year period, as described further above, and (ii) a decrease in accounts receivable primarily attributable to the timing of receipt of payments for certain Medicaid receivables.

*Investing Activities.* The change in net cash provided by (used in) investing activities for the six months ended December 31, 2024 compared to the six months ended December 31, 2023 was primarily due to the effect of (i) the $23.9 million acquisition of the two de novo centers acquired from Concerto in the prior year period and (ii) a $3.3 million increase in proceeds from the sale of short-term investments in the current year period compared to the prior year period.

*Financing activities.* The increase in net cash used in financing activities for the six months ended December 31, 2024 compared to the six months ended December 31, 2023 was primarily due to $5.9 million used for the repurchase of the Company's stock in the current year period.

### Emerging Growth Company and Smaller Reporting Company

We qualify as an “emerging growth company” pursuant to the provisions of the Jumpstart Our Business Startups (“JOBS”) Act and a “smaller reporting company” as defined by the Exchange Act. For as long as we are an “emerging growth company” or a “smaller reporting company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” or “smaller reporting companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, only being required to present two years of audited financial statements, plus unaudited condensed consolidated financial statements for applicable interim periods and the related discussion in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, exemptions from the requirements of holding non-binding advisory “say-on-pay” votes on executive compensation and stockholder advisory votes on golden parachute compensation.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the longer phase-in periods for the adoption of new or revised financial accounting standards under the JOBS Act until we are no longer an emerging growth company. Our election to use the phase-in periods permitted by this election may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the longer phase-in periods permitted under the JOBS Act and who will comply with new or revised financial accounting standards. If we were to subsequently elect instead to comply with public company effective dates, such election would be irrevocable pursuant to the JOBS Act.

### Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different assumptions or conditions, impacting our reported results of operations and financial condition.

Certain accounting estimates involve significant judgments and assumptions by management, which have a material impact on the carrying value of assets and liabilities and the recognition of income and expenses. We consider these accounting estimates to be critical accounting estimates. The estimates and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances.

For a description of our estimates regarding our critical accounting estimates, see “Critical Accounting Estimates” in the 2024 10-K.

## Market risk

As filed, 3,480 characters.

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.

### Interest rate risk

As of December 31, 2024, we had total outstanding debt of $61.9 million in principal amount under the Term Loan Facility, $2.2 million under the convertible term loan, and no outstanding debt under the Revolving Credit Facility (each as defined in Note 8, “Long-Term Debt” to our condensed consolidated financial statements). As of June 30, 2024, we had total outstanding debt of $63.8 million in principal amount under the Term Loan Facility and $2.2 million under the convertible term loan. As of December 31, 2024, the interest rate on the Term Loan Facility was 6.94%. We are exposed to changes in interest rates as a result of our variable-rate borrowings under the 2021 Credit Agreement. Generally, the Company may designate specific borrowings under the 2021 Credit Agreement as either base rate borrowings or Secured Overnight Financing Rate (“SOFR”) borrowings. We amended our 2021 Credit Agreement during fiscal year 2024 to replace the London Interbank Offered Rate (“LIBOR”) reference rate with SOFR prior to the discontinuance of LIBOR. As of December 31, 2024, based on our secured net leverage ratio, the margins of our borrowings under the Term Loan Facility and Revolving Credit Facility (as defined in Note 8, “Long-Term Debt” to our condensed consolidated financial statements) were all SOFR borrowings.

We had cash and cash equivalents of $46.1 million and $56.9 million as of December 31, 2024 and June 30, 2024, respectively, which are deposited with high credit quality financial institutions and are primarily in demand deposit accounts.

Our cash and cash equivalents and interest payments in respect of our debt are subject to market risk due to changes in interest rates. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on our business, financial condition or results of operations.

We had short-term investments of $40.8 million and $45.8 million as of December 31, 2024 and June 30, 2024, respectively, which are primarily invested in managed income funds managed by major financial institutions. The funds mainly invest in investment grade, U.S. denominated short-term fixed and floating rate debt securities. Securities are subject to market risk and sensitive to changes in interest rates. While the instruments held by the funds are generally less sensitive to interest rate changes than instruments with longer maturities due to their short-term nature, the funds may face a heightened level of interest rate risk due to changes in monetary policy. During periods when interest rates are low or negative, the funds yields, and total returns may also be low, or the funds may be unable to maintain positive returns. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on these short-term investments.

### Inflation risk

Based on our analysis of the periods presented, we believe that inflation has not had a material effect on our operating results. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.

## Controls and procedures

As filed, 894 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2024.

### Changes in Internal Control Over Financial Reporting

There have been no changes in internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Feb 4, 2025.
Source: SEC EDGAR, the filing index for accession 0001834376-25-000003. Last ingested by Listed: Nov 5, 2026, 21:06 ET. No prices; not investment advice.
